title: [Antitumoral effect of gamma-interferon in patients with hepatocellular carcinoma].
abstract: The antitumoral effect of gamma-Interferon (Re-IFN-gamma, KW-2202) on nine patients with hepatocellular carcinoma (HCC) has been investigated. gamma-IFN was administered intravenously biweekly at a dose of 8-24 x 10(6) units/day for 5 consecutive days. As all patients had measurable disease determined by an abdominal CT, the antitumoral effect was evaluated by CT, according to the criteria of Koyama and Saito, During gamma-IFN therapy, one patient, who received a total of 4.4 x 10(8) units of gamma-IFN, achieved a partial response (PR) 133 days after onset of treatment. Another patient showed a minor response (MR) 43 days after start of therapy. The duration of the PR and MR were 7.8 weeks and 10.8 weeks, respectively. Two patients were assessed as having had no change (NC), and 5 patients as still manifesting a progressive disease (PD). Marked falls in serum alpha-fetoprotein levels during therapy were observed in 2 cases of which one was graded as having obtained a PR, and the other, a NC. The toxicities observed were fever, general malaise, headaches, and joint pains, which were slight and transient in most cases. In one case, however, a therapy was stopped because of a continuous and severe shoulder pain with no metastasis. Further studies on the use of IFN, possibly in combination with other chemotherapeutic agents, should be performed in patients with HCC.
authors: Gastroenterology Division, Saitama Cancer Center.
authors: Y
authors: Y
authors: Kanda
authors: K
authors: K
authors: Futatsugi
authors: K
authors: K
authors: Saifuku
authors: R
authors: R
authors: Kuwatsuru
authors: S
authors: S
authors: Akazawa
authors: T
authors: T
authors: Fujiki
authors: K
authors: K
authors: Yamamoto
authors: S
authors: S
authors: Yoon
authors: M
authors: M
authors: Ishii
authors: T
authors: T
authors: Nakajima
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000628:therapy*; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D011994:Recombinant Proteins; D000509:alpha-Fetoproteins; D007371:Interferon-gamma